Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hyperthermia payment boost

This article was originally published in The Gray Sheet

Executive Summary

CMS proposes to raise reimbursement for procedure codes applicable to BSD Medical's cancer treatment systems by 86% in the 2008 hospital outpatient payment 1proposal released July 16, according to the firm. CMS will finalize the rates in November, to be effective Jan. 1. BSD markets hyperthermia systems, which kill cancer cells with focused heat and may improve the effectiveness of radiation and chemotherapy by increasing blood flow. The firm filed a response July 30 to questions FDA had on its March PMA submission for the BSD-2000 deep hyperthermia system, providing new data from a Dutch study with 12-year follow-up of patients treated with advanced cervical cancer (2"The Gray Sheet" Jan. 9, 2006, p. 15)...

You may also be interested in...



BSD Medical Plans To File PMA For Cancer Therapy, Prepares Japanese Strategy

BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

UsernamePublicRestriction

Register

MT025126

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel